Telemedicine assists in the management of proatherogenic dyslipidemia and postprandial glucose variability in patients with type 2 diabetes mellitus: a cross-sectional study

Endocr Connect. 2021 Jun 1:EC-21-0209.R1. doi: 10.1530/EC-21-0209. Online ahead of print.


OBJECTIVE: Coronary heart disease (CHD) is a prevalent complication of type 2 diabetes mellitus (T2DM). The proatherogenic low-density lipoprotein (LDL) cholesterol is an established risk factor of cardiovascular disease, and evidence also suggests that postprandial plasma glucose (PPG) levels closely delineate CHD mortality in diabetes. The investigators hypothesized that the addition of telehealth consultation to standard antidiabetic therapy may help to reduce postprandial glucose variability and plasma LDL cholesterol levels in patients with T2DM.

METHODS: This cross-sectional study enrolled patients with newly diagnosed T2DM who received standard antidiabetic therapy with or without additional telehealth consultation. Participants received blood tests for plasma lipid profile and glucose levels at diagnosis of diabetes and after one month of therapeutic intervention. Laboratory results were compared between treatment groups to determine the efficacy of complementary telehealth consultation.

RESULTS: Three hundred and seventy-five participants were enrolled. The standard treatment group had considerably greater levels of plasma LDL cholesterol than recipients of telehealth consultation (110 mg/dL vs. 93.1 mg/dL, P<0.001). Moreover, patients receiving standard treatment had greater levels of fasting plasma glucose (104 mg/dL vs. 98.5 mg/dL, P = 0.027), 2-hour PPG (169 mg/dL vs. 111 mg/dL, P<0.001), and postprandial glucose variability (65.4 mg/dL vs. 12.8 mg/dL, P<0.001) than participants under telehealth consultation.

CONCLUSIONS: Telemedicine in addition to standard antidiabetic therapy helped to reduce plasma LDL cholesterol levels and postprandial glucose variability in patients with newly diagnosed T2DM. Therefore, telehealth consultation is a suitable complement to pharmacologic therapy for diabetic patients to assist in the management of proatherogenic dyslipidemia and postprandial glucose variability.

PMID:34137735 | DOI:10.1530/EC-21-0209